Despite surgical and medical advances, the prognosis for patients with high-grade gliomas remains grim. To address this challenge, we propose a continuation of a research project that combines innovative nanomedicines with convection-enhanced delivery (CED). CED is a local drug delivery technique in which therapeutic agents are infused into the brain through catheters over a period of hours to days: this approach provides large distribution of therapeutic agents in the target region of interest. In our recent work, we have demonstrated that CED of brain-penetrating nanoparticles loaded with chemotherapeutic drugs produces dramatic increases in the survival of animals with intracranial gliomas. The therapeutic effect is even more striking when the nanoparticles are loaded with drugs that exert high cytotoxic activity against glioma stem cells (GSCs), known as the most important cells in the development and persistence of brain tumors. In this past work, we have produced brain-penetrating nanoparticles of the simplest possible design, to facilitate clinical translation of first-generation therapies. In this renewal application, we will build on this progress by testing the effect of new nanoparticle features that should enhance their activity against brain tumors. These new features are inspired by observations about brain tumor biology: (1) adenosine receptors, which are expressed on the surface of tumor cells and tumor-associated microglia, are important regulators of the brain tumor microenvironment, and can make GSCs more sensitive to chemotherapy drugs; and (2) nanoparticles enter cells primarily through endocytosis, and thus effective endosomal escape is essential for biological activity of many intracellular agents. We used these observations to generate hypotheses, which we will test by designing and synthesizing novel polymer nanoparticles. The nanoparticles are composed of block copolymers of poly(lactic acid)-hyperbranched polyglycerols (PLA-HPG) and acid-sensitive, poly(amine-co- esters) (PACE); these novel brain-penetrating nanoparticles will be administered by CED to animals with intracranial tumors. We will test these nanoparticles in three parallel specific aims: (1) covalent attachment of adenosine to the surface of nanoparticles loaded with chemotherapy drugs to sensitize GSCs and enhance treatment of intracranial tumors; (2) incorporation of acid-sensitive PACE into nanoparticles to enhance endosomal escape and, therefore, biological activity of anti-miRs, which will be tested for synergy with chemotherapy drugs; and (3) characterization of nanoparticle toxicity, biodistribution, and cellular tropism when administered by CED. Our work on these parallel aims will lead to the development of multifunctional nanoparticles that provide enhanced tumor killing when administered by CED, and are optimized for clinical translation.

Public Health Relevance

Glioblastoma multiforme (GBM), a common primary malignant brain tumor in adults, has an extremely poor prognosis: even with the best current therapies, the five-year survival is ~3%. This research project aims to develop a new therapeutic strategy based on the infusion of drug-loaded nanoparticles directly into the tumor, in order to specifically target and kill the tumor cells. We believe that this treatment method will prevent the recurrence of the tumor and significantly improve survival of patients with GBM.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA149128-07
Application #
9297226
Study Section
Special Emphasis Panel (ZRG1-OTC-C (02)M)
Program Officer
Fu, Yali
Project Start
2011-03-01
Project End
2021-05-31
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
7
Fiscal Year
2017
Total Cost
$384,846
Indirect Cost
$147,346
Name
Yale University
Department
Engineering (All Types)
Type
Schools of Engineering
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Lopez Sambrooks, Cecilia; Baro, Marta; Quijano, Amanda et al. (2018) Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Res 78:5094-5106
Chen, Evan M; Quijano, Amanda R; Seo, Young-Eun et al. (2018) Biodegradable PEG-poly(?-pentadecalactone-co-p-dioxanone) nanoparticles for enhanced and sustained drug delivery to treat brain tumors. Biomaterials 178:193-203
Baro, Marta; Lopez Sambrooks, Cecilia; Quijano, Amanda et al. (2018) Oligosaccharyltransferase Inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity. Clin Cancer Res :
Jiang, Yuhang; Gaudin, Alice; Zhang, Junwei et al. (2018) A ""top-down"" approach to actuate poly(amine-co-ester) terpolymers for potent and safe mRNA delivery. Biomaterials 176:122-130
Chi, David Lei; Song, Eric; Gaudin, Alice et al. (2017) Improved threshold selection for the determination of volume of distribution of nanoparticles administered by convection-enhanced delivery. Comput Med Imaging Graph 62:34-40
King, Amanda R; Corso, Christopher D; Chen, Evan M et al. (2017) Local DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas. Mol Cancer Ther 16:1456-1469
Seo, Young-Eun; Bu, Tom; Saltzman, W Mark (2017) Nanomaterials for convection-enhanced delivery of agents to treat brain tumors. Curr Opin Biomed Eng 4:1-12
Song, Eric; Gaudin, Alice; King, Amanda R et al. (2017) Surface chemistry governs cellular tropism of nanoparticles in the brain. Nat Commun 8:15322
Adams, Brian D; Wali, Vikram B; Cheng, Christopher J et al. (2016) miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer. Cancer Res 76:927-39
Saucier-Sawyer, Jennifer K; Seo, Young-Eun; Gaudin, Alice et al. (2016) Distribution of polymer nanoparticles by convection-enhanced delivery to brain tumors. J Control Release 232:103-12

Showing the most recent 10 out of 30 publications